Teligent

Teligent developed and marketed a portfolio of nearly 40 generic topical products in the US, several branded/generic injectable drugs including cephalosporins for hospital use, as well as about two branded injectable products. The company also offered contract manufacturing services. Its pipeline focused on expanding into complex generics including sterile injectables and ophthalmic projects.

In recent years the company faced financial challenges. As of early 2022/2023 it filed for bankruptcy protection and ceased most operations—thus it should be considered inactive as an independent entity at present.

Clinical results are not applicable since these are generic drugs with established efficacy/safety profiles.

Pipeline breadth was moderate (~40+ marketed or late-stage ANDA programs), with ongoing expansion into new dosage forms before closure.

No novel clinical data reported due to focus on generics.

Note that there was another unrelated telecom company named Teligent based in Virginia—this profile refers only to the pharma entity headquartered in New Jersey.